Fmcna - Monticello is a medicare approved dialysis facility center in Monticello, Arkansas and it has 16 dialysis stations. It is located in Drew county at 774 Jordan Dr, Monticello, AR, 71655. You can reach out to the office of Fmcna - Monticello at (870) 367-3100. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fmcna - Monticello has the following ownership type - Profit. It was first certified by medicare in March, 1997. The medicare id for this facility is 042543 and it accepts patients under medicare ESRD program.
| Name | Fmcna - Monticello |
|---|---|
| Location | 774 Jordan Dr, Monticello, Arkansas |
| No. of Dialysis Stations | 16 |
| Medicare ID | 042543 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 774 Jordan Dr, Monticello, Arkansas, 71655 | |
| (870) 367-3100 | |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
| NPI Number | 1285746180 |
| Organization Name | Monticello Dialysis |
| Doing Business As | Jefferson County Dialysis Inc |
| Address | 774 Jordan Dr Monticello, Arkansas, 71655 |
| Phone Number | (870) 367-3100 |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 30 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 10 |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 68 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 588 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fmcna - Monticello with elevated calcium levels.
| Patients with hypercalcemia | 68 |
| Hypercalcemia patient months | 588 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 70 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 24 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 25 |
| Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 46 |
| Patient months included in arterial venous fistula and catheter summaries | 372 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 63 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 14 |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 48 |
| Hospitalization Rate in facility | 173.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 318.5 |
| Hospitalization Rate: Lower Confidence Limit | 98.6 |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Fmcna - Monticello were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 29.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 44.3 |
| Readmission Rate: Lower Confidence Limit | 18.1 |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fmcna - Monticello get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .21 (As Expected) |
| SIR: Upper Confidence Limit | 1.01 |
| SIR: Lower Confidence Limit | .01 |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fmcna - Monticello's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 42 |
| Transfusion Rate in facility | 63.8 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 150.3 |
| Transfusion Rate: Lower Confidence Limit | 30.1 |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Fmcna - Monticello lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 240 |
| Mortality Rate in facility | 17.8 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 25.9 |
| Mortality Rate: Lower Confidence Limit | 11.7 |
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago
News Archive
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.
› Verified 4 days ago